Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $55 Million - $61.9 Million
192,626 New
192,626 $55.6 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $1.75 Million - $2.06 Million
-7,909 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $10.5 Million - $13.3 Million
-59,347 Reduced 88.24%
7,909 $1.74 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $8.17 Million - $9.15 Million
45,061 Added 203.02%
67,256 $12.2 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $4.16 Million - $4.91 Million
22,195 New
22,195 $4.48 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $1.41 Million - $1.75 Million
-7,050 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $1.18 Million - $1.58 Million
7,050 New
7,050 $1.54 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.